Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDRelmada Therapeutics Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 3 | -$0.21 | -$0.19 | -$0.20 |
| Q2 2026 | 3 | -$0.18 | -$0.17 | -$0.18 |
| Q3 2026 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q4 2026 | 1 | -$0.20 | -$0.20 | -$0.20 |
| Q1 2027 | 1 | -$0.27 | -$0.27 | -$0.27 |
| Q2 2027 | 1 | -$0.30 | -$0.30 | -$0.30 |
| Q3 2027 | 1 | -$0.32 | -$0.32 | -$0.32 |
| Q4 2027 | 1 | -$0.35 | -$0.35 | -$0.35 |
Relmada Therapeutics Inc Earnings Date And Information
Relmada Therapeutics Inc last posted its earnings results on Thursday, March 19th, 2026. The company reported $-0.27 earnings per share for the quarter, missing analysts' consensus estimates of $-0.14 by $0.13. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Relmada Therapeutics Inc has generated $-1 earnings per share over the last year ($-1.45 diluted earnings per share) and currently has a price-to-earnings ratio of -9.28. Relmada Therapeutics Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Relmada Therapeutics Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/19/2026 | Q4 2025 | -$0.14 | -$0.29 | -0.15 | $0 | $0 |
| 11/13/2025 | Q3 2025 | -$0.04 | -$0.30 | -0.26 | $0 | $0 |
| 08/07/2025 | Q2 2025 | -$0.25 | -$0.30 | -0.05 | N/A | $0 |
| 05/12/2025 | Q1 2025 | -$0.31 | -$0.58 | -0.27 | N/A | $0 |
| 03/27/2025 | Q4 2024 | -$0.70 | -$0.62 | 0.08 | N/A | $0 |
| 11/07/2024 | Q3 2024 | -$0.65 | -$0.72 | -0.07 | N/A | $0 |
| 08/07/2024 | Q2 2024 | -$0.83 | -$0.59 | 0.24 | N/A | $0 |
| 05/08/2024 | Q1 2024 | -$0.90 | -$0.72 | 0.18 | N/A | $0 |
| 03/19/2024 | Q4 2023 | -$0.88 | -$0.84 | 0.04 | N/A | $0 |
| 11/08/2023 | Q3 2023 | -$0.95 | -$0.73 | 0.22 | N/A | $0 |
| 08/08/2023 | Q2 2023 | -$0.92 | -$0.84 | 0.08 | N/A | $0 |
| 05/11/2023 | Q1 2023 | -$0.88 | -$0.87 | 0.01 | N/A | $0 |
| 03/23/2023 | Q4 2022 | -$1.33 | -$1.26 | 0.07 | N/A | $0 |
| 11/10/2022 | Q3 2022 | -$1.40 | -$1.31 | 0.09 | N/A | $0 |
| 08/11/2022 | Q2 2022 | -$1.30 | -$1.33 | -0.03 | N/A | $0 |
| 05/05/2022 | Q1 2022 | -$1.21 | -$1.40 | -0.19 | N/A | $0 |
| 03/25/2022 | Q4 2021 | N/A | -$1.80 | N/A | N/A | $0 |
| 11/12/2021 | Q3 2021 | N/A | -$2.44 | N/A | N/A | $0 |
| 08/10/2021 | Q2 2021 | -$1.47 | -$1.56 | -0.09 | N/A | $0 |
| 05/12/2021 | Q1 2021 | -$1.39 | -$1.34 | 0.05 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Relmada Therapeutics Inc Earnings: FAQ's
The conference call for Relmada Therapeutics Inc's latest earnings report can be listened to online.
The conference call transcript for Relmada Therapeutics Inc's latest earnings report can be read online.
Relmada Therapeutics Inc (:RLMD) has a recorded net income of $-57,385,163.Relmada Therapeutics Inc has generated $-1.45 earnings per share over the last four quarters.
Relmada Therapeutics Inc (:RLMD) has a price-to-earnings ratio of -9.28 and price/earnings-to-growth ratio is -0.14.